ProBioGen Will License GlymaxX® to Thermo Fisher Scientific for Use in Developing Allergy Diagnostics
ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding te…
ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding te…
ProBioGen AG and Tizona Therapeutics, Inc. have signed a commercial license and service agreement for cell line and proc…
. GlymaxX® GlymaxX® is a technology to permanently modify animal cells to produce afucosylated antibodies/proteins (ha…
ProBioGen AG announced today that it has signed a non-exclusive commercial multi-product licensing agreement with Novart…
ProBioGen AG and Merus B.V. today announced that the companies have signed a non-exclusive commercial option and license…
Another global pharma company has licensed ProBioGen's GlymaxX® ADCC-enhancement technology. The license covers the modi…
ProBioGen announces the launch of a comprehensive set of engineered, royalty-free biopharmaceutical CHO production cell…
ProBioGen announced the implementation of its new "Pathway Modulator Technology", a permanent modification of animal cel…
ProBioGen and Inhibrx signed a multi-program license deal on ADCC-enhanced therapeutic antibodies. ProBioGen's GlymaxX®…
Boehringer Ingelheim and ProBioGen AG announced today that they have signed a non-exclusive Licensing Agreement regardin…